Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG , a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

    Media contacts

    Maura Bergen

    Novartis Pharmaceuticals Corporation

    862-778-4146 (direct)

    917-334-0903 (mobile) (onsite in New Orleans)

    


    Heather Rose

    Novartis Pharmaceuticals Corporation

    862-778-1414 (direct)

    917-859-4086 (mobile)





Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:10/8/2008)...ornell University Food Scientists Expand Testing U...tivity Assay, PORTLAND, Maine, Oct. 8 /PRNewswire...today with the release of results from a new study...er commonly consumed,fruits like apples, bananas, ...ing the Cellular Antioxidant Activity (CAA) assay....
(Date:10/8/2008)...N, France, Oct. 8 /- Vical Incorporat...linical data and new nonclinical data,demonstratin...broadly,applicable in DNA- and protein-based infec...ccines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s...l present the data today,Wednesday, October 8, at...
(Date:10/7/2008)...NT, Mich., Oct. 7 /- McLaren Health C...ring some of the world,s leading medical,minds to ... breast and,gastrointestinal cancer treatments. Th...CI, was organized by McLaren,s Sukamal Saha, M.D.,...n sentinel node mapping for,colorectal cancer has ...
(Date:10/7/2008)...ults of FLEXX Trial Presented at the Osteoarthriti...ress, PARSIPPANY, N.J., Oct. 7 /- Fe...lts from the FLEXX Trial of Osteoarthritis of the,...ate), a highly pure,non-avian high molecular weigh... is superior to intra-articular saline (IA-saline)...
Breaking Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4IDM Pharma Announces Upcoming Clinical Data Presentations 674 1IDM Pharma Announces Upcoming Clinical Data Presentations 674 2IDM Pharma Announces Upcoming Clinical Data Presentations 674 3IDM Pharma Announces Upcoming Clinical Data Presentations 674 4Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 2ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 1ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 2Kosan to Reacquire Epothilone Program From Roche 1518 1Kosan to Reacquire Epothilone Program From Roche 1518 2Kosan to Reacquire Epothilone Program From Roche 1518 3Kosan to Reacquire Epothilone Program From Roche 1518 4
...linical study of,HGS-ETR1 -, ROCKVILLE, Md., April...ciences, Inc. today reported that clinical and pre...g that its TRAIL receptor,antibodies, HGS-ETR1 (ma...icant potential for use in the treatment of a broa...d HGS-ETR2 could offer novel, highly,targeted ther...
...llaGenex,Pharmaceuticals, Inc. (NASDAQ:CGPI) today... of the Journal of the American Academy,of Dermato...trials,demonstrated the efficacy and safety of an... doxycycline, USP capsules) for the,treatment of r...tablish the first important body of evidence suppo...
Other Medicine Technology:Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 2Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 3Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 4Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 5Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4
(Date:10/12/2008)... Birdstep Technology,s high availability embedded ...carrier grade OSE RTOS. , ...Technology (OSE: BIRD) today announced the release...ing system. This is the latest platform to be adde...d platforms., , ,"We recognized the importanc...
(Date:10/11/2008)...ould Not Pose Setback and Expects the 89-Year-Old ... ASHEVILLE, N.C., Oct. 11 /PRNewswire/ -- Evangeli...in Montreat, N.C. upon his release this,afternoon ...g a brief stay.,He was admitted for observation af... late Friday., Mr. Graham,s physicians said that ...
(Date:10/11/2008)...ernational Transcends Cultural Divides, JOHANNESB...frican and,international audiences welcome Bishop ...fying gathering, which for the first time is being...tp://www.newscom.com/cgi-bin/prnh/20081011/CLSA011...off with performances by,South Africa,s own multi-...
(Date:10/10/2008)... those already on drugs, some diagnoses could be w...althDay News) -- A new study questions the commonl...e ( C. difficile ) infections are always preceded ...iversity and the Jewish General Hospital found tha...cquired C. difficile infections before hospitali...
Breaking Medicine News(10 mins):Health News:Birdstep Technology Adds ENEA's OSE RTOS to the List of Operating Systems Supported by Their RDM Server, Embedded Database Product 2Health News:Billy Graham Returns Home Following Hospital Observation 2Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Antibiotics May Not Cause Diarrheal Bacteria 2
...yan governmment said Tuesday the rate of HIV/AIDS ...e still posed a a major challenge in the country....CC) said the rate fell from 6.1 percent in 2004 to...nt of the country's nearly 35 million people. "Of...
...etic version of a molecule found in the egg cells ...provide the world with the first drug treatment fo...es the sugary coating found on a tumour cell and b... invading the cell and inactivating the RNA it con...
...s is understood as the perception of noise in the ...nal source of sound, without any vibratory cochlea...rnal noise is produced). It is estimated that bet...uffered tinnitus at some time in their lives, acco...
...t study has found that a substance derived from th...rtain kinds of cancer cells. The study, conducte...ested that this substance could lead to a novel tr...mmon type of lung cancer. The compound, called be...
Other Medicine News:Health News:Brain Tumor Drug in Frogs A New Report 2Health News:Tinnitus Patients can Lead a Normal Life 2Health News:Tinnitus Patients can Lead a Normal Life 3Health News:Tinnitus Patients can Lead a Normal Life 4Health News:Tinnitus Patients can Lead a Normal Life 5Health News:Tree Bark Substance may Hold New Lung-cancer Treatment 2
Restylane is a gel of hyaluronic acid generated by,Streptococcus species of bacteria, chemically crosslinked,with BDDE, stabilized and suspended in phosphate,buffered saline at pH = 7 and concentrati
SCULPTRA™ is an injectable implant that contains microparticles of poly-L-lactic acid, a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. SCULPTRA is reconsti
The HEMOCHRON Response is a whole blood coagulation monitoring instrument designed to be used at the point-of-care. The Response includes an easy-to-read screen and data management features, includin
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo
Medicine Products: